NCT06349343View on ClinicalTrials.gov

CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

CD19/BCMA CAR-T cell therapy

CD19/BCMA CAR-T cell will be infused intravenously at 3 doses: Dose A, Dose B, Dose C.

Trial Locations (1)

Unknown

RECRUITING

Union Hospital Tongji Medical College HUAZHONG University of Science and Technology, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER